Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report

Yubao Wang, Kermit V. Speeg, William Kenneth Washburn, Glenn Halff

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

A case of hepatocellular carcinoma (HCC) with pulmonary recurrence after liver transplantation for HCC is presented in this report. The patient showed disease progression on sorafenib therapy demonstrated by computed tomography scans as well as serial serum α-fetoprotein (AFP) elevation. After his immunosuppression therapy was successfully transitioned to sirolimus and a continuation of sorafenib, he achieved partial remission based on RECIST criteria and normalization of AFP. Mammalian target of rapamycin inhibitors including sirolimus alone or in conjunction with sorafenib may be useful in the treatment of post transplant HCC.

Original languageEnglish (US)
Pages (from-to)5518-5522
Number of pages5
JournalWorld Journal of Gastroenterology
Volume16
Issue number43
DOIs
StatePublished - Nov 21 2010

Keywords

  • Hepatocellular carcinoma
  • Liver transplantation
  • Mammalian target of rapamycin inhibitor
  • Sirolimus
  • Sorafenib

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report'. Together they form a unique fingerprint.

Cite this